{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1%2C+Placebo+Group&page=12",
    "query": {
      "intervention": "Part 1, Placebo Group",
      "page": 12
    },
    "page_size": 10
  },
  "pagination": {
    "page": 12,
    "page_size": 10,
    "total_count": 279,
    "total_pages": 28,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1%2C+Placebo+Group&page=13&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+1%2C+Placebo+Group&page=11&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T11:49:26.619Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07028749",
      "title": "Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "MAR001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marea Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 316,
      "start_date": "2025-06-30",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-15T11:49:26.619Z",
      "location_count": 26,
      "location_summary": "Anniston, Alabama • Mobile, Alabama • Little Rock, Arkansas + 23 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Hamden",
          "state": "Connecticut"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07028749"
    },
    {
      "nct_id": "NCT03100149",
      "title": "A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "RO7046015",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 316,
      "start_date": "2017-06-27",
      "completion_date": "2031-12-01",
      "has_results": true,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-10-15T11:49:26.619Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03100149"
    },
    {
      "nct_id": "NCT06491550",
      "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "AZD4144- Part A",
          "type": "DRUG"
        },
        {
          "name": "Placebo- Part A",
          "type": "DRUG"
        },
        {
          "name": "AZD4144- Part B",
          "type": "DRUG"
        },
        {
          "name": "Placebo- Part B",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin and Furosemide- Part C",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin, Furosemide, and AZD4144 Part C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 91,
      "start_date": "2024-07-15",
      "completion_date": "2025-06-11",
      "has_results": false,
      "last_update_posted_date": "2025-07-04",
      "last_synced_at": "2026-10-15T11:49:26.619Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Brooklyn, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06491550"
    },
    {
      "nct_id": "NCT06112990",
      "title": "Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "creatine monohydrate",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Home-based, telehealth",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 200,
      "start_date": "2023-11-09",
      "completion_date": "2028-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-10-15T11:49:26.619Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06112990"
    },
    {
      "nct_id": "NCT05307679",
      "title": "A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dup15q Syndrome"
      ],
      "interventions": [
        {
          "name": "Basmisanil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "2 Years to 14 Years"
      },
      "enrollment_count": 7,
      "start_date": "2022-12-16",
      "completion_date": "2024-03-04",
      "has_results": true,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-15T11:49:26.619Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Chicago, Illinois",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05307679"
    },
    {
      "nct_id": "NCT06276556",
      "title": "Extension Study of ABP-671 in Participants With Gout",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Gout"
      ],
      "interventions": [
        {
          "name": "ABP-671",
          "type": "DRUG"
        },
        {
          "name": "Allopurinol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Atom Therapeutics Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "19 Years to 75 Years"
      },
      "enrollment_count": 43,
      "start_date": "2024-04-22",
      "completion_date": "2024-09-05",
      "has_results": false,
      "last_update_posted_date": "2025-07-16",
      "last_synced_at": "2026-10-15T11:49:26.619Z",
      "location_count": 33,
      "location_summary": "Tempe, Arizona • Tucson, Arizona • Anaheim, California + 24 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06276556"
    },
    {
      "nct_id": "NCT06562907",
      "title": "Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Weight Management"
      ],
      "interventions": [
        {
          "name": "GS-4571",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Omeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 134,
      "start_date": "2024-08-28",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-15T11:49:26.619Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • San Antonio, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06562907"
    },
    {
      "nct_id": "NCT02546960",
      "title": "A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ExPEC4V (4 : 4 : 4 : 4)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ExPEC4V (4 : 4 : 4 : 8)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ExPEC4V (8 : 8 : 8 : 8)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ExPEC4V (8 : 8 : 8 : 16)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ExPEC4V (16 : 16 : 16 : 16)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 848,
      "start_date": "2015-11-12",
      "completion_date": "2019-06-21",
      "has_results": false,
      "last_update_posted_date": "2020-04-22",
      "last_synced_at": "2026-10-15T11:49:26.619Z",
      "location_count": 17,
      "location_summary": "Mesa, Arizona • Hollywood, Florida • Leesburg, Florida + 14 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Leesburg",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02546960"
    },
    {
      "nct_id": "NCT05047185",
      "title": "Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema",
        "Hereditary Angioedema Type I",
        "Hereditary Angioedema Type II",
        "Hereditary Angioedema Types I and II",
        "Hereditary Angioedema Attack",
        "Hereditary Angioedema With C1 Esterase Inhibitor Deficiency",
        "Hereditary Angioedema - Type 1",
        "Hereditary Angioedema - Type 2",
        "C1 Esterase Inhibitor Deficiency",
        "C1 Inhibitor Deficiency"
      ],
      "interventions": [
        {
          "name": "Deucrictibant low dose",
          "type": "DRUG"
        },
        {
          "name": "Deucrictibant high dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharvaris Netherlands B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 34,
      "start_date": "2022-04-19",
      "completion_date": "2025-06-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-10-15T11:49:26.619Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05047185"
    },
    {
      "nct_id": "NCT02413255",
      "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TAK-020",
          "type": "DRUG"
        },
        {
          "name": "TAK-020 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 120,
      "start_date": "2015-03-18",
      "completion_date": "2017-05-04",
      "has_results": true,
      "last_update_posted_date": "2019-01-07",
      "last_synced_at": "2026-10-15T11:49:26.619Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02413255"
    }
  ]
}